Details of the Drug Reposition

General Information of This Drug (ID: DM8S6T7)

Drug Name
Ivosidenib   DM8S6T7
Synonyms
UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cholangiocarcinoma DIS71F6X 2C12.10 Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Haematological malignancy DISCDP7W 2B33.Y Phase 1 [3]
------------------------------------------------------------------------------------

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health.